News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Quest PharmaTech Inc. and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer


1/28/2008 3:00:36 PM

EDMONTON, Jan. 28 /CNW/ - Quest PharmaTech Inc. ("Quest" or the "Company") today announced that it has signed a collaborative research agreement with the BC Cancer Agency (the "BCCA") to develop a combination therapy for the treatment of lung cancer. The potential treatment will utilize the Company's lead oncology product, SL052, with various immunotherapeutic agents. Research has shown that photodynamic therapy (PDT) can augment the therapeutic effects of immunomodulators such as antibodies, antigens, cytokines and immunoadjuvants in cancer patients.

Read at Canada NewsWire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES